Sleep peptide

DSIP (Delta Sleep-Inducing Peptide)

FDA's May 2026 evaluation gives a plasma half-life of 8 minutes for DSIP (emideltide); the app lists 0.2 hours, about 12 minutes.1

Anecdotal evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

DSIP (Delta Sleep-Inducing Peptide) after one dose: 50% at ~0.2 h, 25% at 0.4 h, 12.5% at 0.6 h.

Drawn from the half-life in the app's model, ~0.2 h. The model's figures

DSIP, also called emideltide, is a nine-amino-acid peptide that FDA's presentation describes as a synthetic nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu.2,1 Kovalzon and Strekalova, in a review in the Journal of Neurochemistry in 2006, write that DSIP "was isolated from rabbit cerebral venous blood by Schoenenberger-Monnier group from Basel in 1977 and initially regarded as a candidate sleep-promoting factor".3 The same review states that "the hypothesis regarding DSIP as a sleep factor is extremely poorly documented and still weak".3 FDA's July 2026 presentation states that neither emideltide (free base) nor emideltide acetate is a component of an FDA-approved drug.2

The app lists the subcutaneous route, while the human studies identified in PubMed and in FDA's evaluation gave DSIP intravenously.4,1 FDA's presentation states there is "No data to support use of emideltide via the nominated SC route of administration (ROA)" for chronic insomnia.2 The app grades the evidence for DSIP as anecdotal.

2

How it works

According to FDA's presentation, animal studies in rabbits, cats and rats reported increases in EEG delta-wave power and spindle activity, and longer sleep duration, after emideltide.2 The opioid antagonist naloxone inhibited emideltide-induced analgesia and prolonged sleep in animals, which FDA reads as suggesting that the effects involve activation of the opioid system.2 FDA's slides state that emideltide "does not appear to bind to or directly interact with opioid receptors" and that, "via a calcium-dependent mechanism", it facilitates the release of enkephalins from neurons in different brain regions; FDA's evaluation traces the binding result to rat brain membranes and human placental membranes, and describes the enkephalin release as reported.2,1 FDA's evaluation states that the primary mechanisms of action, off-target actions and pharmacokinetic profile of emideltide-related substances are unknown.1 Kovalzon and Strekalova write that "the link between DSIP and sleep has never been further characterized, in part because of the lack of isolation of the DSIP gene, protein and possible related receptor".3

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~0.2 h
Bioavailability
80%
Typical dose
100–300 mcg/dose
Route
SubQ
Time to peak
~0.5 h

Sources in this part

  1. 1U.S, 2026

The middle column of the table holds the app's own figures, shown beside what FDA's evaluation reports.

Table 3.1Half-life and pharmacokinetics4 rows
ParameterApp's figureReported in the sources
Half-life~0.2 h (about 12 minutes)FDA's evaluation gives a plasma half-life of 8 minutes; it also cites 3-6 minutes in dogs and about 2-3 minutes in rats and a monkey after intravenous injection (Kato and colleagues, 1984), and 5-10 minutes in human serum incubated in vitro (Graf and colleagues, 1987)1
Bioavailability (SubQ)80%FDA's evaluation reports limited pharmacokinetic information for intravenous administration and states there was no information for the proposed subcutaneous route1
Time to peak~0.5 hIn dogs given a bolus intravenous injection, cerebrospinal fluid concentrations of emideltide peaked 30 minutes after injection in a study (Banks and colleagues, 1982) summarised by FDA; this is not a plasma time to peak after subcutaneous injection1
Typical dose100–300 mcg/doseDoses in the human studies were intravenous and per kilogram, 25 to 150 nmol/kg across the studies FDA summarises (see the doses section)1

FDA states that the short half-life "appears to be due primarily to its rapid hydrolysis into shorter peptides rather than its aggregation or protein binding".1

4

Human studies

A ClinicalTrials.gov query for "delta sleep-inducing peptide" on 16 November 2026 returned 90 records, and none of the 20 shown concerned DSIP. The studies below were identified in PubMed and in FDA's evaluation, which states that it identified clinical data only for intravenous administration.1 FDA's evaluation concludes that for chronic insomnia the results "appear to be inconclusive and at best preliminary".1

Table 4.1Human studies7 rows
Study and yearDesignPeopleDose and lengthMain result
Schneider-Helmert and Schoenenberger, Experientia 19814Randomised, double-blind, intra-subject placebo-controlled crossover, as FDA describes it16 middle-aged people with chronic insomnia425 nmol/kg intravenously over 4 minutes before bedtime; three nights1The authors report longer sleep duration and fewer interruptions, with sleep-promoting effects "only in the second hour after injection"; FDA's evaluation states that emideltide "did not influence SOL" (sleep onset latency) or final waking times compared with placebo4,1
Schneider-Helmert, European Neurology 19875Described by the author as placebo-controlled and double-blind; FDA reads it as externally matched controlled, with no placebo arm5,114 middle-aged people with chronic insomnia530 nmol/kg intravenously on 7 successive nights5,1Author: "Efficiency of night sleep and daytime rest reached the levels of normal controls"; mean sleep onset latency of 58.4 minutes at baseline fell to 38.9 minutes after the first injection and 27.6 minutes after the last (FDA's evaluation)5,1
Monti and colleagues, International Journal of Clinical Pharmacology Research 19876Double-blind crossover, DSIP or placebo66 people with severe chronic insomnia (FDA's evaluation)125 nmol/kg intravenously over 4 nights; the procedure was repeated twice with a four-day washout (FDA's evaluation)6,1Nocturnal awakenings and other waking measures were lower under DSIP, but "no significant differences were found in comparison to baseline or to double-blind placebo nights"; total sleep time and NREM sleep time were increased, and for NREM sleep time and stage 2 sleep the differences from placebo were significant but "the same differences existed already for the baseline values"; the authors conclude the improvement "is of little clinical significance"6
Bes and colleagues, Neuropsychobiology 19927Double-blind, matched-pairs, parallel-groups; glucose solution as placebo716 people with chronic insomnia725 nmol/kg intravenously (or glucose) in the afternoon before each of 3 nights, in a 5-night laboratory stay7Higher sleep efficiency and shorter sleep latency with DSIP than placebo; the authors write that the significant effects "were weak and in part could be due to an incidental change in the placebo group"7
Dick and colleagues, European Neurology 19848Open-label, uncontrolled (FDA's evaluation)1107 inpatients in withdrawal: 47 from alcohol, 60 from opiates825 nmol/kg intravenously, up to 6 injections a day for up to 6 days (FDA's evaluation)2Symptoms and signs "disappeared after DSIP administration or improved markedly and rapidly" in 97% of opiate and 87% of alcohol cases; anxiety was slower to decrease, and opiate withdrawal had a more prolonged course with more injections than alcohol withdrawal; 13% (alcohol) and 22% (opiate) did not meet the requirements for evaluation8
Backmund and colleagues, Journal of Clinical Psychopharmacology 1998 (as summarised by FDA)1Open-label, no comparison group17 people with opioid dependence135 nmol/kg intravenously on a fixed schedule for 7 days2Mean SOWS 1 withdrawal score fell from 34.4 one hour before the first injection to 17.8 after it; only two subjects received all scheduled injections and successfully detoxified1
Pomfrett and colleagues, European Journal of Anaesthesiology 20099Randomised; saline controls924 women, ASA I or II, under propofol and isoflurane anaesthesia9Single intravenous bolus of 25, 50 or 100 nmol/kg given awake and again after induction9DSIP "significantly increased heart rate, decreased HRV" and at 25 nmol/kg reduced delta rhythm and increased bispectral index; the authors conclude it "probably reduced parasympathetic tone"9

Deeper analysis: Schneider-Helmert 1987, 14 people with chronic insomnia

Schneider-Helmert reported the study in European Neurology in 1987, in 14 middle-aged people with chronic insomnia who received DSIP "under placebo-controlled, double-blind conditions for 7 successive nights".5 Polysomnograms were obtained at placebo baseline, at the beginning and end of DSIP treatment, and on one placebo posttreatment night, and daytime state and performance were tested before and after 6 injections.5 The author concludes that "the study demonstrates the efficacy of DSIP for the treatment of impaired sleep and daytime functions as well".5 FDA's evaluation reports mean wake after sleep onset falling from 120.8 minutes at baseline to 78 and then 65.6 minutes, and mean total sleep time rising from 313 minutes to 363.1 and then 385 minutes, after the first and last injections.1 FDA's evaluation states that "there was no placebo arm in the study" and that it interpreted the design as externally matched controlled, comparing the 14 people with an age- and sex-matched external group of healthy subjects.1 FDA lists "the small sample size and poor study methodology" as limiting interpretation of whether the changes in 14 people were clinically meaningful.1 The PubMed record for this paper shows no funding statement or declaration of the author's interests.5

Deeper analysis: Bes 1992, 16 people with chronic insomnia

Bes and colleagues, of the Faculty of Psychology at the University of Amsterdam, reported a double-blind matched-pairs parallel-groups study in Neuropsychobiology in 1992.7 Participants slept for 5 consecutive nights in the laboratory, with night 1 for adaptation and night 2 for baseline, and half received 25 nmol/kg DSIP intravenously and half a glucose solution before each of nights 3 to 5.7 The results indicated higher sleep efficiency and shorter sleep latency with DSIP than with placebo, and one measure of subjectively estimated tiredness decreased within the DSIP group.7 The authors write that "the statistically significant effects were weak and in part could be due to an incidental change in the placebo group", and that "none of the other measures, including subjective sleep quality, showed any change".7 They conclude that "short-term treatment of chronic insomnia with DSIP is not likely to be of major therapeutic benefit".7 FDA's evaluation notes that the sleep latency of the placebo group on the second treatment night was "considerably higher" than on other nights, so FDA calls for caution in interpreting the latency difference.1 FDA's evaluation also reports that emideltide-treated subjects had a numerically shorter sleep onset latency than placebo and that there was no significant difference in objective sleep measures or subjective sleep quality between the groups.1 The PubMed record shows no funding statement or declaration of the authors' interests.7

Deeper analysis: Dick 1984, withdrawal from alcohol and opiates

Dick and colleagues reported the study in European Neurology in 1984; FDA's evaluation places it at the University Hospital of Psychiatry in Geneva, Switzerland.8,1 The authors write that, from animal studies, "it has been postulated that DSIP possesses an agonistic activity on opiate receptors and might be of value in the treatment of withdrawal syndromes".8 FDA's slides, by contrast, state that emideltide "does not appear to bind to or directly interact with opioid receptors".2 The assessment "was based on the clinical evaluation by the physician and the nursing staff".8 In FDA's account of the 60 people who used opioids, 40 who were assessed were reported to show a good decrease or complete disappearance of objective signs, and some who were judged successfully treated had a relapse of anxiety with marked insomnia within 24 to 72 hours after treatment stopped, with "only 13 subjects" not experiencing insomnia.1 The authors write that "tolerance to the DSIP treatment was good, aside from headaches reported by a few patients".8 FDA's slides list the limitations as "small sample size, lack of blinding, absence of comparison group, use of subjective" assessments, with the methods used to confirm outcomes not adequately described.2 FDA's evaluation states that the authors noted the DSIP used was provided by Hoffman-La Roche & Cie S.A., Basel; the PubMed record shows no funding statement.1

Deeper analysis: Backmund 1998, opioid detoxification

Backmund and colleagues reported an open-label study in seven people meeting the DSM-4 diagnosis of opioid dependence, as summarised in FDA's evaluation, which also reports that they received 35 nmol/kg intravenously on a fixed schedule over 7 days.1 FDA states that "only two subjects received all scheduled emideltide injections and successfully detoxified", that these two required doxepin on day 3 to treat insomnia, and that recurrence of withdrawal symptoms was not suppressed after the second and later injections except in one subject.1 The authors write that "it remains an open question whether DSIP could be an effective alternative detoxification approach" and call for further placebo-controlled studies to verify effectiveness.1 FDA lists the limitations as small sample size, lack of blinding and absence of a comparison group, and notes that the timepoint of the post-injection score was not provided by the authors.2 The emideltide in the study was provided by Strathmann AG & Co., Hamburg, Germany, according to FDA's evaluation; no funding statement is quoted there.1

Other human reports

The 1981 Experientia study reports that sleep-promoting effects "occurred only in the second hour after injection" and that "in the first hour a slight arousing effect was indicated", with no day-time sedation or other side effects reported.4 Schoenenberger, a co-author of that paper, belongs to the group that Kovalzon and Strekalova credit with isolating DSIP in 1977.4,3 For narcolepsy, FDA identified one case report (Schneider-Helmert 1984) of a 35-year-old man treated with intravenous emideltide, in which sleep attacks and naps were reduced; FDA states the single-subject report limits interpretation.2

5

Doses reported in studies and on labels

DSIP has no label in the sources reviewed: FDA states that emideltide is not a component of an FDA-approved drug and that it is not a registered drug in "any country searched".2 The doses below come from studies, were given intravenously and are expressed per kilogram, and FDA's evaluation gives 25 nmol/kg as 21.3 µg/kg.1

Table 5.1Doses reported in studies and on labels9 rows
SourceDose and routeSchedule and durationComparator and n
Schneider-Helmert and Schoenenberger 1981125 nmol/kg intravenously over 4 minutesOne injection before bedtime on each of 3 nights (placebo-emideltide-placebo or the reverse)Placebo, intra-subject crossover; n=6
Schneider-Helmert 1987130 nmol/kg intravenously7 successive nightsNo placebo arm; own baseline and external healthy group; n=14
Monti and colleagues 1987125 nmol/kg intravenously over 4 minutes4 nights, repeated twice with a four-day washoutPlacebo crossover; n=6
Bes and colleagues 1992725 nmol/kg intravenouslyAfternoon before each of nights 3, 4 and 5Glucose placebo, parallel groups; n=16
Dick and colleagues 1984225 nmol/kg intravenouslyUp to 6 injections a day for up to 6 days, on request or at fixed intervals every 6-8 hours for 3 daysNo comparison group; n=60 on opiates and 47 on alcohol
Backmund and colleagues 1998135 nmol/kg intravenouslyFixed schedule over 7 days: 4 to 6 injections on day 1, 4 on days 2 to 4, 2 on days 5 to 7No comparison group; n=7
Pomfrett and colleagues 2009925, 50 or 100 nmol/kg intravenous bolusGiven while awake and again after induction of anaesthesiaSaline; 12 on DSIP and 12 on saline
All intravenous studies in FDA's summary125 to 150 nmol/kg intravenously1 to 15 days209 subjects in total; no study of the subcutaneous route identified
The app's range100–300 mcg/dose, subcutaneousThe app does not state a scheduleNo matching study dose in the sources reviewed
6

Side effects reported

Sources in this part

  1. 1U.S, 2026
  2. 2U.S, 2026

FDA's search of its Adverse Event Reporting System (FAERS) for emideltide through 3 March 2024 "retrieved zero reports", and FDA did not identify relevant case reports in the medical literature.1 FDA's slides add that "the lack of reports for emideltide does not imply that the substance is safe or lacks toxicities".2 FDA's evaluation states that doses of 25 – 150 nmol/kg have been given intravenously to 209 subjects for 1 to 15 days, and that for chronic insomnia intravenous emideltide was reported as "well tolerated and not associated with significant AEs".1 In the Dick study of 107 people in withdrawal, FDA's slides report no significant adverse events in 95, 9 people with "minor side effects (e.g., perspiration, headache, nausea, vertigo)", and 3 with serious adverse events: hypotension at the first injection in 2 and repetitive episodes of general discomfort with perspiration and nausea in 1.2 FDA's evaluation adds that there was no additional information for one of these subjects, who received a second injection and experienced "progressive hypotension".1 FDA adds that adverse effects in withdrawal are confounded by the underlying symptoms, and that "safety for emideltide-related products is insufficiently characterized".1 FDA's slides state that emideltide "poses a risk for immunogenicity, potentially amplified by" aggregation and peptide-related impurities.2 FDA's evaluation states that because emideltide can be metabolised by peptidyl dipeptidase A in brain microvessel cells, "clinically relevant drug-drug interactions may occur" with drugs that inhibit dipeptidase, such as captopril.1 FDA states that it did not identify nonclinical studies assessing the abuse potential of emideltide-related substances, although stimulation of the opioid system "could lead to development of addiction".1,2

FDA's evaluation of emideltide for the 503A Bulks List is dated 11 May 2026 and was prepared for the Pharmacy Compounding Advisory Committee meeting of 23 and 24 July 2026.1,10 FDA proposed that emideltide (free base) and emideltide acetate not be included on the 503A Bulks List, stating that a balancing of the criteria "weighs against" their inclusion.10,2 FDA's presentation bases this on the substances being "not well characterized" physically and chemically, insufficient safety data, immunogenicity concerns, and a lack of evidence of effectiveness in chronic insomnia, narcolepsy and opioid withdrawal.2 FDA's presentation states that emideltide "is a common name and not a USAN, INN, or IUPAC name", and that it is not recognised in the European, Japanese or International Pharmacopeias.2 RAPS reports that the committee "voted against recommending emideltide for inclusion on the 503A Bulks List in a narrow 6-7 vote with one abstention".11 The same report states that the committee voted in favor of adding six of the seven peptides it reviewed, and that "FDA will ultimately determine whether to approve or reject" the recommendations.11 A law firm commentary states that the committee's recommendations "are not binding on the FDA, which must still undertake formal rulemaking before any substance is permanently added to the list".12 The same commentary reports that on 15 April 2026 FDA announced its intent to remove emideltide (DSIP) from Category 2 of its interim 503A Bulks List because the nomination was withdrawn, and adds that "Removal from Category 2 does not render these bulk drug substances eligible for compounding under section 503A".12 The WADA 2026 Prohibited List text does not name DSIP, delta sleep-inducing peptide or emideltide.13 Its section S2 states that "the following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited"; the sources reviewed do not say whether DSIP falls under that wording.13

8

What is not known

Sources in this part

  1. 1U.S, 2026
  2. 2U.S, 2026

FDA's evaluation did not identify clinical studies of the subcutaneous route, for effectiveness or for safety.2 FDA's slides list "No information on benefit from long-term administration" of intravenous emideltide among the limitations of the insomnia studies.2 A PubMed query for delta sleep-inducing peptide limited to systematic review and meta-analysis publication types returned 0 records on 16 November 2026. For the bulk drug substances emideltide (free base) and emideltide acetate, FDA lists "Lack of certain critical characterization data, such as impurities", including aggregates and bacterial endotoxin levels.2 Where the app's 80% bioavailability and 0.5-hour time to peak come from is not stated in the sources reviewed, which report no subcutaneous pharmacokinetic data.1

What is DSIP?

DSIP, also called emideltide, is a nine-amino-acid peptide that Kovalzon and Strekalova say was isolated from rabbit cerebral venous blood in 1977.1,3

What is the half-life of DSIP?

FDA's evaluation gives a plasma half-life of 8 minutes, and the app lists about 0.2 hours (12 minutes).1 The same evaluation cites 3-6 minutes in dogs after intravenous injection and 5-10 minutes in human serum in vitro.1

How long does DSIP take to reach its peak level?

The app lists a time to peak of about 0.5 hours, and FDA's evaluation identified no pharmacokinetic study of subcutaneous DSIP.1 In dogs given an intravenous injection, cerebrospinal fluid concentrations peaked 30 minutes after injection in a study summarised by FDA.1

Is DSIP approved by the FDA?

FDA's presentation states that neither emideltide (free base) nor emideltide acetate is a component of an FDA-approved drug.2

How did the FDA advisory committee vote on DSIP?

RAPS reports that the Pharmacy Compounding Advisory Committee voted against recommending emideltide for the 503A Bulks List, 6-7 with one abstention.11 FDA will ultimately determine whether to approve or reject the committee's recommendations, so the vote is not an FDA decision.11

Is DSIP banned by WADA?

The WADA 2026 Prohibited List text does not name DSIP, delta sleep-inducing peptide or emideltide.13 The list also prohibits "other substances with similar chemical structure or similar biological effect(s)" to the named peptide hormones, and the sources reviewed do not say whether DSIP falls under that wording.13

Did DSIP improve sleep in human studies?

The small intravenous studies in people with chronic insomnia did not all reach the same conclusion, and FDA's evaluation calls the results "inconclusive and at best preliminary".1 Bes and colleagues wrote that short-term treatment with DSIP "is not likely to be of major therapeutic benefit", while Schneider-Helmert wrote that the study "demonstrates the efficacy of DSIP" for impaired sleep and daytime functions.7,5

Has DSIP been studied as a subcutaneous injection?

FDA's evaluation did not identify clinical studies of subcutaneous emideltide, and the human studies it describes gave the peptide intravenously.1

What side effects of DSIP have been reported?

FDA's search of its Adverse Event Reporting System through 3 March 2024 retrieved zero reports for emideltide.1 In the Dick study of 107 people in withdrawal, FDA's slides report 9 people with minor side effects (perspiration, headache, nausea, vertigo) and 3 with serious adverse events, including hypotension at the first injection in 2.2

11

References

  1. U.S. Food and Drug Administration. FDA Evaluation of Emideltide-Related Bulk Drug Substances (Emideltide (free base) and Emideltide acetate). Briefing document for the Pharmacy Compounding Advisory Committee meeting of 23-24 July 2026, dated 11 May 2026. FDA evaluation
  2. U.S. Food and Drug Administration. Emideltide-related bulk drug substances. Presentation slides, Pharmacy Compounding Advisory Committee meeting, 24 July 2026. FDA slides
  3. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem 2006. PMID 16539679
  4. Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia 1981. PMID 7028502
  5. Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol 1987. PMID 3622582
  6. Monti JM, et al. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. Int J Clin Pharmacol Res 1987. PMID 3583493
  7. Bes F, et al. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology 1992. PMID 1299794
  8. Dick P, et al. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. Eur Neurol 1984. PMID 6548969
  9. Pomfrett CJ, et al. Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia. Eur J Anaesthesiol 2009. PMID 19142086
  10. U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026 (points to consider). FDA briefing cover document
  11. Regulatory Affairs Professionals Society. FDA advisory committee backs two more peptides, rejects one for compounding list. RAPS, July 2026. RAPS report
  12. Asebey EJ. FDA to Remove 12 Popular Peptides from the Category 2 "Do Not Compound" List. Frier Levitt, 16 April 2026. Frier Levitt article
  13. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list